Phase II Trial Comparing 3 vs 4 Fractions of Brachytherapy for Cervical Cancer

This study is looking at two ways to give radiation therapy (brachytherapy) for locally advanced cervical cancer. You would receive either 3 fractions (doses) of 8 Gy each, or 4 fractions of 7 Gy each, which is the current standard treatment. The main goal is to see how many patients can successfully complete the 3-fraction treatment. To join, you must have cervical cancer and be planning to receive brachytherapy, be at least 18 years old, and be able to understand and sign a consent form. The study is currently unclear on its recruitment status.

Study design
This is a non-randomized clinical trial, meaning you would not be randomly assigned to a treatment group. It plans to enroll 41 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The proportion of patients receiving the 3-fraction regimen will be measured up to 8 months after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07022470

Phase II Trial Comparison of 3 vs 4 Fractions (BRACHY-FIT).

Recruiting
PHASE2Ages 18+InterventionalTreatment
Stanford University
~41 participants
Updated 2026-06-12 on ClinicalTrials.gov
What's tested:3-Fraction HDR Brachytherapy4-Fraction HDR Brachytherapy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of Patients Receiving 3-Fraction Brachytherapy Regimen
Measured over Up to 8 months
Cervical Cancers
1 sites across 1 states
California1
  • Elizabeth Kidd, MD · PRINCIPAL_INVESTIGATOR · Stanford University

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histologically documented malignancy of the cervix and planned to receive brachytherapy as part of definitive treatment.
ECOG performance status of 0-2
Age ≥ 18 years old.
Ability to understand and the willingness to provide written informed consent.

Exclusion

Contraindication to receiving radiotherapy as determined by treating radiation oncologist.
Contraindication to receiving MRI.
Prior radiation to the pelvis \> 3 months ago
Age \< 18 years old.
Pregnant or breast-feeding
  • Proportion of Patients Receiving 3-Fraction Brachytherapy RegimenUp to 8 months

    Proportion of patients that underwent a 3 fraction brachytherapy regimen.